$22.2M in expenses

Working with scientists from the U.S. National Cancer Institute and other organizations, perform basic research and preclinical efficacy assessments of new molecular entities being developed for the prevention and treatment of infectious disease, with particular emphasis on pathogenic agents of interest to the biodefense community. Working with the Department of Defense and other agencies, support the development of vaccines and therapeutic entities for infectious agents. Working with scientists from the U.S. National Institutes of Health and other agencies, perform preclinical assessments of small molecule therapeutics and biotherapeutics being developed for the treatment of stroke, tissue fibrosis, neurologic diseases, and other disease entities.